Journal
CELL
Volume 181, Issue 7, Pages 1518-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2020.05.005
Keywords
-
Categories
Funding
- NIH [DP1AI124669, T32 GM007388]
- Princeton DFR Innovation Funds for New Ideas in Science
- National Science Foundation (NSF) [PHY-1734030]
- FCRF, National Cancer Institute [NCI-CCSG P30CA072720-5921]
Ask authors/readers for more resources
The rise of antibiotic resistance and declining discovery of new antibiotics has created a global health crisis. Of particular concern, no new antibiotic classes have been approved for treating Gram-negative pathogens in decades. Here, we characterize a compound, SCH-79797, that kills both Gram-negative and Gram-positive bacteria through a unique dual-targeting mechanism of action (MoA) with undetectably low resistance frequencies. To characterize its MoA, we combined quantitative imaging, proteomic, genetic, metabolomic, and cell-based assays. This pipeline demonstrates that SCH-79797 has two independent cellular targets, folate metabolism and bacterial membrane integrity, and outperforms combination treatments in killing methicillin-resistant Staphylococcus aureus (MRSA) persisters. Building on the molecular core of SCH-79797, we developed a derivative, lrresistin-16, with increased potency and showed its efficacy against Neisseria gonorrhoeae in a mouse vaginal infection model. This promising antibiotic lead suggests that combining multiple MoAs onto a single chemical scaffold may be an underappreciated approach to targeting challenging bacterial pathogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available